Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Mucopolysaccharidosis I
Conditions
Mucopolysaccharidosis I, Hurler Syndrome, Hurler-Scheie Syndrome, Scheie Syndrome
Trial Timeline
Dec 1, 2005 → Oct 1, 2006
NCT ID
NCT00258011About Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
Aldurazyme (Recombinant Human Alpha-L-Iduronidase) is a phase 3 stage product being developed by Sanofi for Mucopolysaccharidosis I. The current trial status is completed. This product is registered under clinical trial identifier NCT00258011. Target conditions include Mucopolysaccharidosis I, Hurler Syndrome, Hurler-Scheie Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00258011 | Phase 3 | Completed |
Competing Products
20 competing products in Mucopolysaccharidosis I